Ineffectiveness of pneumococcal vaccination in cardiovascular prevention: The CAPAMIS study

JAMA Internal Medicine

Volumn 173, Issue 20, 2013, Pages 1918-1920

  Vila Corcoles, Angel ^a   Ochoa Gondar, Olga ^a   Rodriguez Blanco, Teresa ^b   De Diego, Cinta ^a   Saatue, Eva ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; BRAIN ISCHEMIA; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INFLUENZA VACCINATION; LETTER; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SPAIN; STROKE;

EID: 84888348006     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.6901     Document Type: Letter

References (6)

1. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: ameta-analysis. CMAJ. 2009;180(1):48-58.
2. Tseng HF, Slezak JM, Quinn VP, Sy LS, Van den Eeden SK, Jacobsen SJ. Pneumococcal vaccination and risk of acute myocardial infarction and stroke in men. JAMA. 2010;303(17):1699-1706.
3. Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, et al. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. BMC Public Health. 2010;10:25.
4. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al EPIVAC Study Group. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up. BMC Public Health. 2012;12:222.
5. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep. 2012;61(21):394-395.
6. Gamez G, Hammerschmidt S. Combat pneumococcal infections: adhesins as candidates for protein-based vaccine development. Curr Drug Targets. 2012;13(3):323-337.